Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60
Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60
复制标题
新型人抗 VEGF 抗体 MIL60 具有有效的抗血管生成和抗肿瘤活性
DOI：
10.1038/cmi.2014.6
复制
发表时间：
2014-05-01
影响因子：
24.1
通讯作者：
Feng, Jiannan
中科院分区：
文献类型：
--
作者：
Yang, Jing;Wang, Qun;Feng, Jiannan
血管生成对于肿瘤的发展、生长和转移至关重要。血管内皮生长因子（VEGF）通过刺激肿瘤相关血管生成促进实体瘤的生长和转移，阻断VEGF的活性可以抑制肿瘤的生长。安维汀是一种人源化抗VEGF抗体，自2004年以来已成功应用于临床。然而，安维汀的价格对中国人来说非常高。在这里，我们报告了一种新的人抗VEGF中和抗体，MIL 60，其显示出与Avastin相当的亲和力（MIL 60的K-D值为44.5 pM，而Avastin的K-D值为42.7 pM）。MIL 60在抑制VEGF触发的内皮细胞增殖（MIL 60的IC 50值为31 +/- 6.4 ng/ml，Avastin的IC 50值为47 +/- 8.1 ng/ml）、迁移（8 μ g/ml或0.8 μ g/ml MIL 60与对照相比：P
Angiogenesis is crucial for tumor development, growth and metastasis. Vascular endothelial growth factor (VEGF) has been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis, and blocking the activity of VEGF can starve tumors. Avastin, which is a humanized anti-VEGF antibody, has been successfully applied in clinics since 2004. However, the price of Avastin is extremely high for Chinese people. Here, we report a novel human anti-VEGF neutralizing antibody, MIL60, which shows an affinity comparable to that of Avastin (the K-D value of MIL60 was 44.5 pM, while that of Avastin was 42.7 pM). MIL60 displays favorable actions in inhibiting VEGF-triggered endothelial cell proliferation (the IC50 value of MIL60 was 31 +/- 6.4 ng/ml and that of Avastin was 47 +/- 8.1 ng/ml), migration (8 mu g/ml or 0.8 mu g/ml MIL60 versus the control: P